GET YOUR EMAIL UPDATES

Dear Breakeros, welcome to the website of the largest psychedelic conference in the known universe. Please sign up to our Breaking Convention newsletter for irregular updates about our events and publications.

Secure and Spam free...

SPEAKERS

img
CLARE S. WILKINS
Founder of Pangea Biomedics

Clare S. Wilkins is a former intravenous drug user & methadone patient who shed her chemical dependencies with the aid of ibogaine in 2005. As founder of Pangea Biomedics, she has facilitated over 600 treatments & has collaborated with MAPS to study the long-term effects of patients undergoing detoxification therapy with ibogaine for opiates. Since 2010 she has been an active board member of The Global Ibogaine Therapy Alliance (GITA) and is a co-author of the Clinical Guidelines for Ibogaine-Assisted Detoxification, a comprehensive risk-management resource & minimum standard of care. Clare also serves on the board of advisors for Symbio Life Sciences. Mentored by Howard Lotsof, she is committed to advancing scientific research of iboga, including ibogaine, its alkaloids & analogs. She is currently collaborating with ICEERS to develop a clinical trial for methadone patients utilizing the cumulative administration method she developed over 10 years of clinical practice in Mexico.
As a member of INPUD, an international drug user rights organization, she is devoted to reducing stigma & harm, promoting the health of people who use drugs & every human’s basic right to medicine.

ABSTRACT

The African psychoactive alkaloid Ibogaine, Schedule 1 in the USA, researched for substance use since the 1950’s, has demonstrated effectiveness in reversing tolerance & craving for opioids, stimulants & alcohol. Risks & fatalities are involved, due to the demographic, screening, inducing bradycardia, prolonging the QT interval & blocking the Potassium hERG channel, further complicated by opioid maintenance medications & psychiatric drugs.

Almost all ibogaine centers, rapidly increasing in number, administer a single “flood” dose, with supplemental amounts over 5-7 days. PAWS is not remediated by this accelerated approach, as abstinence symptoms persist for months.

I will present a case of a 17 year methadone dependency, using cumulative doses of ibogaine & decreased doses of methadone over 6 weeks. She has remained opiate-free for over 1 year. Supported with data from ECGs & standard measures, this case demonstrates that it may be safer & efficacious to administer ibogaine incrementally over time.